source
- GSK halts Phase 3 chronic cough drug camlipixant, jeopardizing $2 billion Bellus Health acquisitionGSK announced it is ending development of camlipixant, a drug aimed at treating refractory chronic cough, after completing Phase 3 trials. The move comes as the company proceeds with its planned $…
- MDCalc introduces quality-rating system for over 800 clinical calculators used by doctorsMDCalc, a health‑technology company, announced a new quality‑rating system that will evaluate the more than 800 clinical calculators doctors rely on for decisions such as kidney function, birth out…